Dennie Jones, M.D.
Professor
About Dennie Jones
Dr. Jones is a Professor with the Division of Hematology & Oncology at the University of Florida. He is a board certified medical oncologist with expertise in the study and treatment of lung cancer. He completed his undergraduate and medical degrees at Washington University in St. Louis, Missouri, then completed in residency in Internal Medicine at the Baylor College of Medicine in Houston, Texas, and then his fellowship in Oncology at the University of Texas MD Anderson cancer Center, where he remained on the faculty. After two years of research at Genentech, Inc., he returned to academic medicine at the University of Texas Medical Branch, and then joined the faculty of the University of New Mexico as the Director of Thoracic Oncology as well as the Medical Director of the New Mexico Cancer Care Alliance.
Teaching Profile
Courses Taught
2018-2022
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2020-2021
BMS6816 Cancer Bio Clin Oncol
2018
MDT7200 Elect Top/Medicine
Clinical Profile
Specialties
- Cancer
Areas of Interest
- Lung Cancer
Research Profile
Areas of Interest
- GI malignancies
- metastatic lung cancer
Publications
2016
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.
ESMO open.
1(5)
[PMID] 27843641.
2014
A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.
Translational oncology.
7(3):349-54
[DOI] 10.1016/j.tranon.2014.03.001.
[PMID] 24746712.
2013
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Oral oncology.
49(5):461-7
[DOI] 10.1016/j.oraloncology.2012.12.016.
[PMID] 23384718.
2012
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
BMC cancer.
12
[DOI] 10.1186/1471-2407-12-449.
[PMID] 23033932.
2010
Development of bronchiolitis obliterans organizing pneumonia with platinum-based chemotherapy for metastatic rectal cancer.
Clinical colorectal cancer.
9(3):177-8
[DOI] 10.3816/CCC.2010.n.024.
[PMID] 20643623.
2007
Response of intracranial metastases to erlotinib therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
25(31):5024-6
[PMID] 17971603.
2006
Gastric cancer: standards for the 21st century.
Critical reviews in oncology/hematology.
57(2):123-31
[PMID] 16412659.
2005
Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman’s disease.
Cancer investigation.
23(2)
[PMID] 15813512.
2005
Endoscopic ultrasound-guided fine-needle aspiration staging of lung cancer: is it time to go beyond cytology?
Chest.
127(2):418-20
[PMID] 15705972.
2004
A case of radiation recall mucositis associated with docetaxel.
Head & neck.
26(2):197-200
[PMID] 14762890.
2004
CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study.
Applied immunohistochemistry & molecular morphology : AIMM.
12(4):315-22
[PMID] 15536330.
2004
Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST).
Cancer biology & therapy.
3(3):251-8
[PMID] 14726714.
2004
The value of a complete blood count in predicting cancer of the colon.
Cancer detection and prevention.
28(1):37-42
[PMID] 15041076.
2003
Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.
Cancer investigation.
21(4):550-2
[PMID] 14533445.
2003
SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome.
Archives of pathology & laboratory medicine.
127(4):e201-4
[PMID] 12683902.
2002
Translocation (15;17) and trisomy 21 in the microgranular variant of acute promyelocytic leukemia.
Cancer genetics and cytogenetics.
132(1):74-6
[PMID] 11801315.
Grants
Mar 2023
ACTIVE
Pragmatica-Lung: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CA
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Oct 2020
ACTIVE
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Nov 2019
– Dec 2022
SMARTPLUS-106: Debio 1143 a SMAC Mimetic in Combination with
Nivolumab in Patients Failing Prior PD-1/PD-L1 Treatment: A Basket
Trial
Role: Principal Investigator
Funding: IQVIA Holdings
via DEBIOPHARM SA
Aug 2019
– Aug 2021
An Open-label, Multi-center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Role: Principal Investigator
Funding: FORTREA
via BAYER HEALTHCARE PHARMACEUTICALS
Jul 2019
ACTIVE
LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jul 2019
– Jul 2024
LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via GENENTECH INC
Jul 2018
– Jul 2023
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Oct 2017
– Oct 2021
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Role: Principal Investigator
Funding: ABBVIE
Feb 2017
– Jan 2023
A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung
Role: Principal Investigator
Funding: TAIHO ONCOLOGY INC
Oct 2016
– Oct 2021
A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual P13K/mTOR Kinase Inhibitor, PF-05212384 (Gedatolisib), in Patients with Advanced or Metastatic Non-Small Cell Carcinoma of the Lung
Role: Principal Investigator
Funding: PFIZER INC
Oct 2016
– Oct 2021
A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, INTERNATIONAL PHASE 2 STUDY OF TAS-114 IN COMBINATION WITH S-1 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Role: Principal Investigator
Funding: MEDPACE
via TAIHO ONCOLOGY INC
May 2015
– Jul 2023
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Role: Principal Investigator
Funding: *CLINIPACE INC
Education
Fellowship – Oncology
1988
·
MD Anderson
Residency – Internal Medicine
1987
·
Baylor College of Medicine
Medical Degree
1985
·
Washington University
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- dvjonesii@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100278
GAINESVILLE FL 32610